Pharma & Healthcare

Global Vaginosis Drug Market Insights, Forecast to 2030

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
The global Vaginosis Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Vaginosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Vaginosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Vaginosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Vaginosis Drug include Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem and Xiuzheng, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Vaginosis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Vaginosis Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Vaginosis Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaginosis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Vaginosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Vaginosis Drug sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
Segment by Type
Rx
OTC
Segment by Application
Hospital
Pharmacy
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Vaginosis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Vaginosis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaginosis Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Vaginosis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Vaginosis Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Rx
1.2.3 OTC
1.3 Market by Application
1.3.1 Global Vaginosis Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Vaginosis Drug Sales Estimates and Forecasts 2019-2030
2.2 Global Vaginosis Drug Revenue by Region
2.2.1 Global Vaginosis Drug Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Vaginosis Drug Revenue by Region (2019-2024)
2.2.3 Global Vaginosis Drug Revenue by Region (2025-2030)
2.2.4 Global Vaginosis Drug Revenue Market Share by Region (2019-2030)
2.3 Global Vaginosis Drug Sales Estimates and Forecasts 2019-2030
2.4 Global Vaginosis Drug Sales by Region
2.4.1 Global Vaginosis Drug Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Vaginosis Drug Sales by Region (2019-2024)
2.4.3 Global Vaginosis Drug Sales by Region (2025-2030)
2.4.4 Global Vaginosis Drug Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Vaginosis Drug Sales by Manufacturers
3.1.1 Global Vaginosis Drug Sales by Manufacturers (2019-2024)
3.1.2 Global Vaginosis Drug Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaginosis Drug in 2023
3.2 Global Vaginosis Drug Revenue by Manufacturers
3.2.1 Global Vaginosis Drug Revenue by Manufacturers (2019-2024)
3.2.2 Global Vaginosis Drug Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaginosis Drug Revenue in 2023
3.3 Global Key Players of Vaginosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Vaginosis Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaginosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaginosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaginosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Vaginosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaginosis Drug Sales by Type
4.1.1 Global Vaginosis Drug Historical Sales by Type (2019-2024)
4.1.2 Global Vaginosis Drug Forecasted Sales by Type (2025-2030)
4.1.3 Global Vaginosis Drug Sales Market Share by Type (2019-2030)
4.2 Global Vaginosis Drug Revenue by Type
4.2.1 Global Vaginosis Drug Historical Revenue by Type (2019-2024)
4.2.2 Global Vaginosis Drug Forecasted Revenue by Type (2025-2030)
4.2.3 Global Vaginosis Drug Revenue Market Share by Type (2019-2030)
4.3 Global Vaginosis Drug Price by Type
4.3.1 Global Vaginosis Drug Price by Type (2019-2024)
4.3.2 Global Vaginosis Drug Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Vaginosis Drug Sales by Application
5.1.1 Global Vaginosis Drug Historical Sales by Application (2019-2024)
5.1.2 Global Vaginosis Drug Forecasted Sales by Application (2025-2030)
5.1.3 Global Vaginosis Drug Sales Market Share by Application (2019-2030)
5.2 Global Vaginosis Drug Revenue by Application
5.2.1 Global Vaginosis Drug Historical Revenue by Application (2019-2024)
5.2.2 Global Vaginosis Drug Forecasted Revenue by Application (2025-2030)
5.2.3 Global Vaginosis Drug Revenue Market Share by Application (2019-2030)
5.3 Global Vaginosis Drug Price by Application
5.3.1 Global Vaginosis Drug Price by Application (2019-2024)
5.3.2 Global Vaginosis Drug Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Vaginosis Drug Market Size by Type
6.1.1 US & Canada Vaginosis Drug Sales by Type (2019-2030)
6.1.2 US & Canada Vaginosis Drug Revenue by Type (2019-2030)
6.2 US & Canada Vaginosis Drug Market Size by Application
6.2.1 US & Canada Vaginosis Drug Sales by Application (2019-2030)
6.2.2 US & Canada Vaginosis Drug Revenue by Application (2019-2030)
6.3 US & Canada Vaginosis Drug Market Size by Country
6.3.1 US & Canada Vaginosis Drug Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Vaginosis Drug Sales by Country (2019-2030)
6.3.3 US & Canada Vaginosis Drug Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Vaginosis Drug Market Size by Type
7.1.1 Europe Vaginosis Drug Sales by Type (2019-2030)
7.1.2 Europe Vaginosis Drug Revenue by Type (2019-2030)
7.2 Europe Vaginosis Drug Market Size by Application
7.2.1 Europe Vaginosis Drug Sales by Application (2019-2030)
7.2.2 Europe Vaginosis Drug Revenue by Application (2019-2030)
7.3 Europe Vaginosis Drug Market Size by Country
7.3.1 Europe Vaginosis Drug Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Vaginosis Drug Sales by Country (2019-2030)
7.3.3 Europe Vaginosis Drug Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Vaginosis Drug Market Size
8.1.1 China Vaginosis Drug Sales (2019-2030)
8.1.2 China Vaginosis Drug Revenue (2019-2030)
8.2 China Vaginosis Drug Market Size by Application
8.2.1 China Vaginosis Drug Sales by Application (2019-2030)
8.2.2 China Vaginosis Drug Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Vaginosis Drug Market Size by Type
9.1.1 Asia Vaginosis Drug Sales by Type (2019-2030)
9.1.2 Asia Vaginosis Drug Revenue by Type (2019-2030)
9.2 Asia Vaginosis Drug Market Size by Application
9.2.1 Asia Vaginosis Drug Sales by Application (2019-2030)
9.2.2 Asia Vaginosis Drug Revenue by Application (2019-2030)
9.3 Asia Vaginosis Drug Sales by Region
9.3.1 Asia Vaginosis Drug Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Vaginosis Drug Revenue by Region (2019-2030)
9.3.3 Asia Vaginosis Drug Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaginosis Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Vaginosis Drug Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Vaginosis Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Vaginosis Drug Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Vaginosis Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Vaginosis Drug Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Vaginosis Drug Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Bayer Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Pfizer Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Sanofi Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Piramal
11.4.1 Piramal Company Information
11.4.2 Piramal Overview
11.4.3 Piramal Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Piramal Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Piramal Recent Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Overview
11.5.3 Abbott Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Abbott Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Abbott Recent Developments
11.6 Galderma
11.6.1 Galderma Company Information
11.6.2 Galderma Overview
11.6.3 Galderma Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Galderma Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Galderma Recent Developments
11.7 Mission
11.7.1 Mission Company Information
11.7.2 Mission Overview
11.7.3 Mission Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Mission Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Mission Recent Developments
11.8 Alkem
11.8.1 Alkem Company Information
11.8.2 Alkem Overview
11.8.3 Alkem Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Alkem Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Alkem Recent Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Company Information
11.9.2 Xiuzheng Overview
11.9.3 Xiuzheng Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Xiuzheng Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Xiuzheng Recent Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Overview
11.10.3 Teva Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Teva Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Teva Recent Developments
11.11 Perrigo
11.11.1 Perrigo Company Information
11.11.2 Perrigo Overview
11.11.3 Perrigo Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Perrigo Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Perrigo Recent Developments
11.12 West-Ward
11.12.1 West-Ward Company Information
11.12.2 West-Ward Overview
11.12.3 West-Ward Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 West-Ward Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 West-Ward Recent Developments
11.13 HPGC
11.13.1 HPGC Company Information
11.13.2 HPGC Overview
11.13.3 HPGC Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 HPGC Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 HPGC Recent Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Company Information
11.14.2 Yunnan Baiyao Overview
11.14.3 Yunnan Baiyao Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 Yunnan Baiyao Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Yunnan Baiyao Recent Developments
11.15 Starpharma
11.15.1 Starpharma Company Information
11.15.2 Starpharma Overview
11.15.3 Starpharma Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 Starpharma Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Starpharma Recent Developments
11.16 Novel
11.16.1 Novel Company Information
11.16.2 Novel Overview
11.16.3 Novel Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.16.4 Novel Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Novel Recent Developments
11.17 Edenvridge
11.17.1 Edenvridge Company Information
11.17.2 Edenvridge Overview
11.17.3 Edenvridge Vaginosis Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.17.4 Edenvridge Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Edenvridge Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaginosis Drug Industry Chain Analysis
12.2 Vaginosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaginosis Drug Production Mode & Process
12.4 Vaginosis Drug Sales and Marketing
12.4.1 Vaginosis Drug Sales Channels
12.4.2 Vaginosis Drug Distributors
12.5 Vaginosis Drug Customers
13 Market Dynamics
13.1 Vaginosis Drug Industry Trends
13.2 Vaginosis Drug Market Drivers
13.3 Vaginosis Drug Market Challenges
13.4 Vaginosis Drug Market Restraints
14 Key Findings in The Global Vaginosis Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Vaginosis Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Rx
Table 3. Major Manufacturers of OTC
Table 4. Global Vaginosis Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 5. Global Vaginosis Drug Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 6. Global Vaginosis Drug Revenue by Region (2019-2024) & (US$ Million)
Table 7. Global Vaginosis Drug Revenue by Region (2025-2030) & (US$ Million)
Table 8. Global Vaginosis Drug Revenue Market Share by Region (2019-2024)
Table 9. Global Vaginosis Drug Revenue Market Share by Region (2025-2030)
Table 10. Global Vaginosis Drug Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 11. Global Vaginosis Drug Sales by Region (2019-2024) & (K Doses)
Table 12. Global Vaginosis Drug Sales by Region (2025-2030) & (K Doses)
Table 13. Global Vaginosis Drug Sales Market Share by Region (2019-2024)
Table 14. Global Vaginosis Drug Sales Market Share by Region (2025-2030)
Table 15. Global Vaginosis Drug Sales by Manufacturers (2019-2024) & (K Doses)
Table 16. Global Vaginosis Drug Sales Share by Manufacturers (2019-2024)
Table 17. Global Vaginosis Drug Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 18. Global Vaginosis Drug Revenue Share by Manufacturers (2019-2024)
Table 19. Global Key Players of Vaginosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 20. Vaginosis Drug Price by Manufacturers 2019-2024 (USD/Dose)
Table 21. Global Vaginosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Vaginosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginosis Drug as of 2023)
Table 23. Global Key Manufacturers of Vaginosis Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Vaginosis Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Vaginosis Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 28. Global Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 29. Global Vaginosis Drug Sales Share by Type (2019-2024)
Table 30. Global Vaginosis Drug Sales Share by Type (2025-2030)
Table 31. Global Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 32. Global Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 33. Global Vaginosis Drug Revenue Share by Type (2019-2024)
Table 34. Global Vaginosis Drug Revenue Share by Type (2025-2030)
Table 35. Vaginosis Drug Price by Type (2019-2024) & (USD/Dose)
Table 36. Global Vaginosis Drug Price Forecast by Type (2025-2030) & (USD/Dose)
Table 37. Global Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 38. Global Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 39. Global Vaginosis Drug Sales Share by Application (2019-2024)
Table 40. Global Vaginosis Drug Sales Share by Application (2025-2030)
Table 41. Global Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 42. Global Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 43. Global Vaginosis Drug Revenue Share by Application (2019-2024)
Table 44. Global Vaginosis Drug Revenue Share by Application (2025-2030)
Table 45. Vaginosis Drug Price by Application (2019-2024) & (USD/Dose)
Table 46. Global Vaginosis Drug Price Forecast by Application (2025-2030) & (USD/Dose)
Table 47. US & Canada Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 48. US & Canada Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 49. US & Canada Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 50. US & Canada Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 51. US & Canada Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 52. US & Canada Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 53. US & Canada Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 54. US & Canada Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 55. US & Canada Vaginosis Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 56. US & Canada Vaginosis Drug Revenue by Country (2019-2024) & (US$ Million)
Table 57. US & Canada Vaginosis Drug Revenue by Country (2025-2030) & (US$ Million)
Table 58. US & Canada Vaginosis Drug Sales by Country (2019-2024) & (K Doses)
Table 59. US & Canada Vaginosis Drug Sales by Country (2025-2030) & (K Doses)
Table 60. Europe Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 61. Europe Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 62. Europe Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 63. Europe Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 64. Europe Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 65. Europe Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 66. Europe Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 67. Europe Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 68. Europe Vaginosis Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 69. Europe Vaginosis Drug Revenue by Country (2019-2024) & (US$ Million)
Table 70. Europe Vaginosis Drug Revenue by Country (2025-2030) & (US$ Million)
Table 71. Europe Vaginosis Drug Sales by Country (2019-2024) & (K Doses)
Table 72. Europe Vaginosis Drug Sales by Country (2025-2030) & (K Doses)
Table 73. China Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 74. China Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 75. China Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 76. China Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 77. China Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 78. China Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 79. China Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 80. China Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 81. Asia Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 82. Asia Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 83. Asia Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 84. Asia Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 85. Asia Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 86. Asia Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 87. Asia Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 88. Asia Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 89. Asia Vaginosis Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 90. Asia Vaginosis Drug Revenue by Region (2019-2024) & (US$ Million)
Table 91. Asia Vaginosis Drug Revenue by Region (2025-2030) & (US$ Million)
Table 92. Asia Vaginosis Drug Sales by Region (2019-2024) & (K Doses)
Table 93. Asia Vaginosis Drug Sales by Region (2025-2030) & (K Doses)
Table 94. Middle East, Africa and Latin America Vaginosis Drug Sales by Type (2019-2024) & (K Doses)
Table 95. Middle East, Africa and Latin America Vaginosis Drug Sales by Type (2025-2030) & (K Doses)
Table 96. Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2019-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2025-2030) & (US$ Million)
Table 98. Middle East, Africa and Latin America Vaginosis Drug Sales by Application (2019-2024) & (K Doses)
Table 99. Middle East, Africa and Latin America Vaginosis Drug Sales by Application (2025-2030) & (K Doses)
Table 100. Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2019-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2025-2030) & (US$ Million)
Table 102. Middle East, Africa and Latin America Vaginosis Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 103. Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2019-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2025-2030) & (US$ Million)
Table 105. Middle East, Africa and Latin America Vaginosis Drug Sales by Country (2019-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America Vaginosis Drug Sales by Country (2025-2030) & (K Doses)
Table 107. Bayer Company Information
Table 108. Bayer Description and Major Businesses
Table 109. Bayer Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 110. Bayer Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bayer Recent Developments
Table 112. Pfizer Company Information
Table 113. Pfizer Description and Major Businesses
Table 114. Pfizer Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 115. Pfizer Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Pfizer Recent Developments
Table 117. Sanofi Company Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 120. Sanofi Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Recent Developments
Table 122. Piramal Company Information
Table 123. Piramal Description and Major Businesses
Table 124. Piramal Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 125. Piramal Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Piramal Recent Developments
Table 127. Abbott Company Information
Table 128. Abbott Description and Major Businesses
Table 129. Abbott Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 130. Abbott Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Abbott Recent Developments
Table 132. Galderma Company Information
Table 133. Galderma Description and Major Businesses
Table 134. Galderma Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 135. Galderma Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Galderma Recent Developments
Table 137. Mission Company Information
Table 138. Mission Description and Major Businesses
Table 139. Mission Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 140. Mission Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Mission Recent Developments
Table 142. Alkem Company Information
Table 143. Alkem Description and Major Businesses
Table 144. Alkem Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 145. Alkem Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Alkem Recent Developments
Table 147. Xiuzheng Company Information
Table 148. Xiuzheng Description and Major Businesses
Table 149. Xiuzheng Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 150. Xiuzheng Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Xiuzheng Recent Developments
Table 152. Teva Company Information
Table 153. Teva Description and Major Businesses
Table 154. Teva Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 155. Teva Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Teva Recent Developments
Table 157. Perrigo Company Information
Table 158. Perrigo Description and Major Businesses
Table 159. Perrigo Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 160. Perrigo Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Perrigo Recent Developments
Table 162. West-Ward Company Information
Table 163. West-Ward Description and Major Businesses
Table 164. West-Ward Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 165. West-Ward Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. West-Ward Recent Developments
Table 167. HPGC Company Information
Table 168. HPGC Description and Major Businesses
Table 169. HPGC Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 170. HPGC Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. HPGC Recent Developments
Table 172. Yunnan Baiyao Company Information
Table 173. Yunnan Baiyao Description and Major Businesses
Table 174. Yunnan Baiyao Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 175. Yunnan Baiyao Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Yunnan Baiyao Recent Developments
Table 177. Starpharma Company Information
Table 178. Starpharma Description and Major Businesses
Table 179. Starpharma Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 180. Starpharma Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Starpharma Recent Developments
Table 182. Novel Company Information
Table 183. Novel Description and Major Businesses
Table 184. Novel Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 185. Novel Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Novel Recent Developments
Table 187. Edenvridge Company Information
Table 188. Edenvridge Description and Major Businesses
Table 189. Edenvridge Vaginosis Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 190. Edenvridge Vaginosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. Edenvridge Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Vaginosis Drug Distributors List
Table 195. Vaginosis Drug Customers List
Table 196. Vaginosis Drug Market Trends
Table 197. Vaginosis Drug Market Drivers
Table 198. Vaginosis Drug Market Challenges
Table 199. Vaginosis Drug Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaginosis Drug Product Picture
Figure 2. Global Vaginosis Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Vaginosis Drug Market Share by Type in 2023 & 2030
Figure 4. Rx Product Picture
Figure 5. OTC Product Picture
Figure 6. Global Vaginosis Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Vaginosis Drug Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Vaginosis Drug Report Years Considered
Figure 12. Global Vaginosis Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Vaginosis Drug Revenue 2019-2030 (US$ Million)
Figure 14. Global Vaginosis Drug Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 15. Global Vaginosis Drug Revenue Market Share by Region (2019-2030)
Figure 16. Global Vaginosis Drug Sales 2019-2030 ((K Doses)
Figure 17. Global Vaginosis Drug Sales Market Share by Region (2019-2030)
Figure 18. US & Canada Vaginosis Drug Sales YoY (2019-2030) & (K Doses)
Figure 19. US & Canada Vaginosis Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 20. Europe Vaginosis Drug Sales YoY (2019-2030) & (K Doses)
Figure 21. Europe Vaginosis Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 22. China Vaginosis Drug Sales YoY (2019-2030) & (K Doses)
Figure 23. China Vaginosis Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 24. Asia (excluding China) Vaginosis Drug Sales YoY (2019-2030) & (K Doses)
Figure 25. Asia (excluding China) Vaginosis Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Vaginosis Drug Sales YoY (2019-2030) & (K Doses)
Figure 27. Middle East, Africa and Latin America Vaginosis Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 28. The Vaginosis Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 29. The Top 5 and 10 Largest Manufacturers of Vaginosis Drug in the World: Market Share by Vaginosis Drug Revenue in 2023
Figure 30. Global Vaginosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 31. Global Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 32. Global Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 33. Global Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 34. Global Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 35. US & Canada Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 36. US & Canada Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 37. US & Canada Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 38. US & Canada Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 39. US & Canada Vaginosis Drug Revenue Share by Country (2019-2030)
Figure 40. US & Canada Vaginosis Drug Sales Share by Country (2019-2030)
Figure 41. U.S. Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 42. Canada Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 43. Europe Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 44. Europe Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 45. Europe Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 46. Europe Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 47. Europe Vaginosis Drug Revenue Share by Country (2019-2030)
Figure 48. Europe Vaginosis Drug Sales Share by Country (2019-2030)
Figure 49. Germany Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 50. France Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 51. U.K. Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 52. Italy Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 53. Russia Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 54. China Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 55. China Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 56. China Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 57. China Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 58. Asia Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 59. Asia Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 60. Asia Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 61. Asia Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 62. Asia Vaginosis Drug Revenue Share by Region (2019-2030)
Figure 63. Asia Vaginosis Drug Sales Share by Region (2019-2030)
Figure 64. Japan Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 65. South Korea Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 66. China Taiwan Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 67. Southeast Asia Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 68. India Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Vaginosis Drug Sales Market Share by Type (2019-2030)
Figure 70. Middle East, Africa and Latin America Vaginosis Drug Revenue Market Share by Type (2019-2030)
Figure 71. Middle East, Africa and Latin America Vaginosis Drug Sales Market Share by Application (2019-2030)
Figure 72. Middle East, Africa and Latin America Vaginosis Drug Revenue Market Share by Application (2019-2030)
Figure 73. Middle East, Africa and Latin America Vaginosis Drug Revenue Share by Country (2019-2030)
Figure 74. Middle East, Africa and Latin America Vaginosis Drug Sales Share by Country (2019-2030)
Figure 75. Brazil Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 76. Mexico Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 77. Turkey Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 78. Israel Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 79. GCC Countries Vaginosis Drug Revenue (2019-2030) & (US$ Million)
Figure 80. Vaginosis Drug Value Chain
Figure 81. Vaginosis Drug Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies